At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 260 enrolled
Drug / intervention
Ixabepilone, 32 mg/m^2 +2 moredrug
Likely dose
Ixabepilone, 32 mg/m^2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, and 1 other intervention for Advanced/Metastatic Non-Small Cell Lung Cancer. Completed, enrolled 260 participants across 33 sites in 10 countries.
Detailed Summary
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, France, Germany, Italy, Russia, South Korea, Spain, Taiwan, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartDec 2008
Primary CompletionMay 2010
Study CompletionAug 2011
TodayJul 2026
First PostedJul 29, 2008
Enrollment StartDec 1, 2008
Primary CompletionMay 1, 2010
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 17.9 years ago
Interventions
Ixabepilone, 32 mg/m^2drug
Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
Paclitaxel, 200 mg/m^2drug
IV solutions, paclitaxel, 200 mg/m\^2
Carboplatin (area under the concentration curve [AUC] 6)drug
Carboplatin (AUC 6) day 1, every 21 days, 6 cycles